Updated on 15.06.2026|12:20 PM
Avience Biomedicals Limited is set to launch its Initial Public Offering (IPO). It is an Indian enterprise engaged in the manufacturing and trading of medical consumables such as In-Vitro Diagnostic (IVD) products, rapid test kits, and biochemistry reagents.
The public issue will open for subscription on Thursday, June 18, 2026, and will close on Monday, June 22, 2026.
Through this 100% book-built fresh issue, the company intends to raise approximately ₹35.94 Crores at the upper price band of ₹208 per share.
The raised capital is primarily earmarked for establishing a new manufacturing facility at the Medical Device Park in YEIDA, Uttar Pradesh, alongside funding ongoing working capital needs.
This IPO review provides the price band and a comprehensive financial review of the company along with strengths and risks of the company.
Briefs of Avience Biomedicals IPO Details:
- Price Band: ₹196 – ₹208 per equity share
- Face Value: ₹10 per share
- IPO Open / Close Dates: June 18, 2026 – June 22, 2026
- Lot Size: 1,200 Shares (Retail Minimum Investment: ₹2,49,600)
- Issue Size: 17,28,000 Equity Shares / ~₹35.94 Crores
- Fresh Issue: 17,28,000 Shares (~₹35.94 Cr)
- Offer for Sale (OFS): Nil
- Registrar: Skyline Financial Services Pvt. Ltd.
- Listing Exchange: NSE EMERGE
IPO Reservation:
The company is offering 17,28,000 shares under the issue. The net offer to the public is allocated across investor categories as follows:
- QIB Portion: Not more than 50% of the Net Issue.
- NII (HNI) Portion: Not less than 15% of the Net Issue.
- Retail (RII) Portion: Not less than 35% of the Net Issue.
What Is The Avience Biomedicals IPO GMP Today?
To view current GMP rates for this and other listings, visit our GMP hub page. For more GMP details check our IPO GMP vs Listing Accuracy Study 2026.
Note that the Grey Market Premium fluctuates daily based on market interest. This number is unofficial and is not regulated by SEBI, NSE, or BSE.
What is the Important Timeline and Allotment Schedule for the Avience Biomedicals IPO?
To assist investors with their capital planning, here is the essential schedule for this public issue.
- IPO Open Date: Thursday, June 18, 2026
- IPO Close Date: Monday, June 22, 2026
- Basis of Allotment Date: Tuesday, June 23, 2026
- Refund Initiation Date: Wednesday, June 24, 2026
- Credit of Shares: Wednesday, June 24, 2026
- Listing Date: Thursday, June 25, 2026
What Are The Objectives of Avience Biomedicals IPO?
The net proceeds raised through the fresh issue are proposed to be deployed towards the following strategic objectives:
- Capital Expenditure: A significant portion of the funds (approximately ₹15.95 Crores) is allocated to partially finance the setup of a new manufacturing unit at the Medical Device Park in YEIDA, Uttar Pradesh. This will enable the company to expand its in-house manufacturing capabilities and broaden its product portfolio.
- Working Capital: Around ₹8.25 Crores will be deployed to meet the projected working capital needs, which have risen due to increased inventory requirements and trade receivables as the business scales.
- General Corporate Purposes: The rest of the money will be used to pay for everyday business needs and activities to grow the brand.
How is The Financial Performance of Avience Biomedicals?
The table below presents a summary of the company's financial performance based on its restated consolidated financial statements.
(Figures in ₹ Crores)
Period Ended | 31 Jan 26 (10M)* | 31 Mar 25 | 31 Mar 2024 | 31 Mar 2023 |
Total Income | 41.94 | 45.97 | 24.37 | 10.93 |
Profit After Tax (PAT) | 5.74 | 7.23 | 2.14 | 0.71 |
EBITDA | 10.34 | 11.41 | 4.08 | 1.43 |
Total Borrowing | 26.73 | 22.16 | 15.13 | 2.66 |
Assets | 66.07 | 56.52 | 34.65 | 10.02 |
Source: RHP
*Data represents the 10-month period ended January 31, 2026.
Financial Analysis & Explanations:
Total Income:
The company demonstrated exceptional revenue scaling, growing from ₹24.37 Crores in FY24 to ₹45.97 Crores in FY25.
This momentum continued robustly in the 10-month period ending January 2026 with ₹41.94 Crores in revenue, driven by a strategic transition towards selling higher volumes of in-house manufactured goods and expanding into export markets like Dubai and Ethiopia.
Profit After Tax (PAT):
Profitability surged remarkably, more than tripling from ₹2.14 Crores in FY24 to ₹7.23 Crores in FY25.
The strong net profit of ₹5.74 Crores in the recent 10-month period highlights excellent operational leverage, as fixed costs are comfortably absorbed over a growing revenue base.
EBITDA:
Operational efficiency improved significantly, with EBITDA jumping to ₹11.41 Crores in FY25.
The EBITDA margin expanded from 17.01% in FY24 to 25.22% in FY25, underscoring the company's pricing power and the higher profitability associated with its manufactured medical products compared to pure trading.
Total Borrowing:
To fund rapid expansion and increasing inventory needs, total borrowings rose to ₹26.73 Crores by January 2026.
This increase is a direct consequence of the working-capital-intensive nature of scaling healthcare operations, though the leverage remains manageable against the growing equity base.
Assets:
The asset base expanded rapidly to ₹66.07 Crores by January 2026.
This growth is largely fueled by necessary investments in capital expenditure for the upcoming YEIDA facility and the buildup in current assets required to support the expanding order book.
What Are The P/E Ratio and Peer Comparison?
To evaluate the company's valuation, we examine the Price-to-Earnings (P/E) ratio based on the top end of the price band
- Issue Price (Upper Band): ₹208
- EPS (FY25): ₹19.06
- P/E Ratio: ~10.91x
Peer Comparison:
The Red Herring Prospectus states that no listed companies in India operate in a business line identical to Avience Biomedicals Limited.
Analysis:
In the absence of direct listed peers, investors cannot perform a standard relative valuation.
However, evaluating the company on its own merits, Avience Biomedicals boasts an exceptionally high Return on Net Worth (RoNW) of 49.89% in FY25.
Entering the market at a P/E multiple of approximately 10.91x based on its FY25 EPS, the pricing appears very reasonable.
Investors must weigh this attractive valuation multiple against the company's rapid fundamental growth and the lack of comparable industry benchmarks.
What is The Industry Outlook of Avience Biomedicals ?
Growth Potential:
The Indian medical device and diagnostics industry is poised for significant expansion, with market projections suggesting it could reach $50 billion by 2030. The continued push for self-reliance and the global expansion of healthcare infrastructure provide strong macroeconomic tailwinds.
Market Trends: There is a clear shift toward localized manufacturing to reduce import dependence for critical diagnostic kits. Avience’s strategic pivot to establish a fully compliant manufacturing unit at a dedicated Medical Device Park aligns perfectly with these industry movements.
What Are The Strengths and Risks of Avience Biomedicals IPO?
Strengths:
- Exceptional Return Ratios: A RoNW of nearly 50% in FY25 indicates excellent management of shareholder equity and highly efficient capital utilisation.
- Strategic Expansion: The planned capital expenditure for the new YEIDA facility provides a clear roadmap for scaling up in-house manufacturing, which historically yields better margins than trading.
- Robust Compliance: Holding critical certifications such as WHO-GMP, ISO 13485, and CE marking ensures eligibility for stringent government and international contracts.
Risks:
- High Concentration: The business is heavily reliant on a few key partners, with the top 10 customers accounting for 46.44% of revenue and the top 10 suppliers for 82.69% of purchases (as of Jan 2026).
- Working Capital Intensity: Extended trade receivables (124 days) and inventory holding periods (173 days) have historically led to negative investing cash flows, placing pressure on overall liquidity.
- Reliance on Trading: Despite the push for manufacturing, trading activities still constitute over 68% of total revenue, leaving margins exposed to third-party supplier pricing and potential supply chain disruptions.
Key Considerations for Investors
Please refer to the minimum investment structure to understand the application and investment requirements for participation in the issue.
- Minimum Application: The lot size is 1,200 Shares, amounting to a minimum retail application of ₹2,49,600. Note: The required investment is higher than the usual ₹2 lakh limit applicable to retail investors, which places such applications closer to the Small-HNI segment for classification purposes.
- Valuation vs. Risk: At a P/E of 10.9x, the pricing is highly attractive relative to the company's rapid growth and high RoNW. However, the lack of listed peers means price discovery will rely entirely on the company's future execution capabilities.
- Promoter Commitment: The promoters currently hold a significant 87.89% stake, demonstrating strong alignment with the company's future performance and ongoing expansion plans.
Key Takeaways
- IPO Price: ₹208 per share (Upper Band).
- Min Investment: ₹2,49,600 (1,200 Shares).
- Valuation: P/E of ~10.91x (No Direct Listed Peers).
- Financials: Revenue ₹45.97 Cr (FY25); High RoNW (49.89%).
- Listing: NSE EMERGE platform on June 25, 2026.
more Important IPO Resources:
1. IPO Market Analytics and Research Page.
3. Daily Details of IPO Subscriptions
4. IPO Listing Performance Tracker 2026 – Complete Dataset of IPO Listing Gains in India
5. Upcoming and Live IPOs of 2026
FAQs on Avience Biomedicals IPO
What is the latest Grey Market Premium (GMP) for the Avience Biomedicals IPO?
The GMP is an unofficial market indicator that changes frequently based on investor sentiment and demand. For the latest updates, please refer to our dedicated GMP section.
What is Avience Biomedicals IPO price band?
The price band is fixed at ₹196 to ₹208 per equity share.
When is the Avience Biomedicals IPO allotment expected to be finalised?
The allotment status is tentatively scheduled to be finalised on June 23, 2026, subject to the completion of the issue process.
Where can applicants verify their Avience Biomedicals IPO allotment status?
The allotment status can be verified on the website of Skyline Financial Services Pvt. Ltd. (Registrar to the Issue) or through the NSE IPO allotment platform.
What is Avience Biomedicals IPO listing date?
The shares are expected to be listed on the stock exchange on Thursday, June 25, 2026.
Investment Perspective on Avience Biomedicals IPO
Avience Biomedicals offers a high-growth opportunity in the diagnostic medical devices sector with very attractive return metrics and a reasonable valuation multiple.
However, the high working capital intensity, customer/supplier concentration, and the elevated minimum investment ticket size are factors that require careful evaluation by prospective investors.
Disclaimer: This article has been published for educational purposes and does not constitute financial or investment advice. Prospective investors should carefully read all scheme-related and offer documents and consider consulting a SEBI-registered investment advisor before making investment decisions.
